Rondaptivon pegol–induced changes in FVIII elimination curves. Original elimination curves (fitted by linear regression) of different FVIII products are depicted as red lines and terminal elimination curves under combined therapy of FVIII concentrates and the VWF-binding aptamer rondaptivon pegol as blue lines. The half-lives as estimated by WAPPS population pharmacokinetics are presented in Table 2 and time to 1% or 5% in the supplemental tables. Patient 9 received only 3 doses of rondaptivon pegol because he did not practice regular prophylaxis.